Their synergistic pharmacology has yielded superior metabolic outcomes in rodent and non-human primate models and human trials of obesity and T2DM than selective GLP-1 mono-therapy (36). This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.